About Korro Bio
Korro Bio is a company based in Cambridge (United States) founded in 2018 by Josh Rosenthal, Andrew Fraley, and Nessan Bermingham.. Korro Bio has raised $4 million across 4 funding rounds from investors including Fidelity Investments, ARE and Citadel. The company has 104 employees as of December 31, 2024. Korro Bio operates in a competitive market with competitors including Beam Therapeutics, Avidity Biosciences, eGenesis, Univercells and Sutro Biopharma, among others.
- Headquarter Cambridge, United States
- Employees 104 as on 31 Dec, 2024
- Founders Josh Rosenthal, Andrew Fraley, Nessan Bermingham
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Korro Bio, Inc.
-
Annual Revenue
$2.27 M0as on Dec 31, 2024
-
Net Profit
$-83.58 M-2.97as on Dec 31, 2024
-
EBITDA
$-88.34 M-9.2as on Dec 31, 2024
-
Total Equity Funding
$4 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
104
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Korro Bio
Korro Bio is a publicly listed company on the NASDAQ with ticker symbol KRRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Korro Bio
Korro Bio has successfully raised a total of $4M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(06 Jun 2019)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Post-IPO - Korro Bio | Valuation |
investors |
|
| Jan, 2022 | Amount | Post-IPO - Korro Bio | Valuation |
investors |
|
| Sep, 2020 | Amount | Post-IPO - Korro Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Korro Bio
Korro Bio has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on tech startups
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Korro Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Korro Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Korro Bio Comparisons
Competitors of Korro Bio
Korro Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, Avidity Biosciences, eGenesis, Univercells and Sutro Biopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Korro Bio
Frequently Asked Questions about Korro Bio
When was Korro Bio founded?
Korro Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Korro Bio located?
Korro Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Korro Bio?
Ram Aiyar is the current CEO of Korro Bio.
Is Korro Bio a funded company?
Korro Bio is a funded company, having raised a total of $4M across 4 funding rounds to date. The company's 1st funding round was a Post-IPO of $91.5M, raised on Jun 06, 2019.
How many employees does Korro Bio have?
As of Dec 31, 2024, the latest employee count at Korro Bio is 104.
What is the annual revenue of Korro Bio?
Annual revenue of Korro Bio is $2.27M as on Dec 31, 2024.
What does Korro Bio do?
Korro Bio was founded in 2018 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where RNA-editing technologies are developed for precision medicine. The OPERA platform is employed to create targeted, single-base RNA edits that modulate protein function. Medical needs of patients with debilitating diseases are addressed through these approaches.
Who are the top competitors of Korro Bio?
Korro Bio's top competitors include Sutro Biopharma, eGenesis and Avidity Biosciences.
Is Korro Bio publicly traded?
Yes, Korro Bio is publicly traded on NASDAQ under the ticker symbol KRRO.
Who are Korro Bio's investors?
Korro Bio has 15 investors. Key investors include Fidelity Investments, ARE, Citadel, Atlas Venture, and Verition Fund Management.
What is Korro Bio's ticker symbol?
The ticker symbol of Korro Bio is KRRO on NASDAQ.